[go: up one dir, main page]

MX2011013150A - Composicion farmaceutica para uso en oftalmologia medica y veterinaria. - Google Patents

Composicion farmaceutica para uso en oftalmologia medica y veterinaria.

Info

Publication number
MX2011013150A
MX2011013150A MX2011013150A MX2011013150A MX2011013150A MX 2011013150 A MX2011013150 A MX 2011013150A MX 2011013150 A MX2011013150 A MX 2011013150A MX 2011013150 A MX2011013150 A MX 2011013150A MX 2011013150 A MX2011013150 A MX 2011013150A
Authority
MX
Mexico
Prior art keywords
medical
pharmaceutical composition
veterinary ophthalmology
ophthalmology
veterinary
Prior art date
Application number
MX2011013150A
Other languages
English (en)
Inventor
Vladimirovich Maxim Skulachev
Original Assignee
Ltd Liability Company Mitotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ltd Liability Company Mitotech filed Critical Ltd Liability Company Mitotech
Publication of MX2011013150A publication Critical patent/MX2011013150A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B69/00—Dyes not provided for by a single group of this subclass
    • C09B69/001—Dyes containing an onium group attached to the dye skeleton via a bridge

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a los campos de farmacéutica y medicina y más específicamente se refiere a la producción y uso de composiciones farmacéuticas de fármacos (preparaciones oftálmicas) que contienen un antioxidante dirigido a mitocondrias y un conjunto de sustancias auxiliares, que se proporcionan para la curación eficaz de las enfermedades oftálmicas en seres humanos y animales.
MX2011013150A 2009-06-10 2009-06-10 Composicion farmaceutica para uso en oftalmologia medica y veterinaria. MX2011013150A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/RU2009/000295 WO2010143990A1 (ru) 2009-06-10 2009-06-10 Фармацевтическая композиция для применения в медицинской и ветеринарной офтальмологии

Publications (1)

Publication Number Publication Date
MX2011013150A true MX2011013150A (es) 2012-03-14

Family

ID=43309061

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011013150A MX2011013150A (es) 2009-06-10 2009-06-10 Composicion farmaceutica para uso en oftalmologia medica y veterinaria.

Country Status (15)

Country Link
US (2) US9724313B2 (es)
EP (2) EP2441453B1 (es)
JP (1) JP5659388B2 (es)
KR (1) KR101478728B1 (es)
CN (2) CN107362157B (es)
AU (1) AU2009347921B8 (es)
BR (1) BRPI0924460A2 (es)
CA (1) CA2764481C (es)
EA (1) EA025414B1 (es)
ES (1) ES2527791T3 (es)
IL (1) IL216702A0 (es)
MX (1) MX2011013150A (es)
UA (1) UA104320C2 (es)
WO (1) WO2010143990A1 (es)
ZA (1) ZA201200111B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2837437C (en) * 2011-06-03 2020-12-15 Mitotech Sa Oral formulations of mitochondrially-targeted antioxidants and their preparation and use
CN102327650B (zh) * 2011-08-25 2014-01-22 高家旗 一种人工晶状体植入手术柔性水溶胶辅剂及其制备方法
RU2506086C1 (ru) * 2012-09-07 2014-02-10 Илья Александрович Марков Глазные капли, обладающие противовоспалительным и антибактериальным действием
US11058677B2 (en) * 2012-12-19 2021-07-13 Novartis Ag LFA-1 inhibitor formulations
RU2510264C1 (ru) * 2012-12-21 2014-03-27 Станислав Анатольевич Кедик Офтальмологический препарат в виде глазных капель, содержащий разветвленные полигексаметиленгуанидины
CN103405766B (zh) * 2013-08-06 2016-01-06 温州医学院眼视光研究院 一种贝伐单抗滴眼液及其制备方法
US9308165B2 (en) * 2013-08-22 2016-04-12 Therapeutic Vision, Inc. Composition for treating ocular effects of diabetes
US11179327B2 (en) 2013-08-28 2021-11-23 Lenz Therapeutics, Inc. Compositions and methods for the treatment of presbyopia
US9314427B2 (en) 2013-08-28 2016-04-19 Presbyopia Therapies Llc Compositions and methods for the improvement of distance vision and the treatment of refractive errors of the eye
US9320709B2 (en) 2013-08-28 2016-04-26 Presbyopia Therapies Llc Storage stable compositions and methods for the treatment of refractive errors of the eye
US9844537B2 (en) 2013-08-28 2017-12-19 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US10064818B2 (en) 2013-08-28 2018-09-04 Presbyopia Therapies, LLC Compositions and methods for the treatment of presbyopia
US10307408B2 (en) 2013-08-28 2019-06-04 Presbyopia Therapies, LLC Contact lens compositions and methods for the treatment of presbyopia
US10617763B2 (en) 2013-08-28 2020-04-14 Presbyopia Therapies, LLC Compositions and methods for the treatment of presbyopia
US9833441B2 (en) 2013-08-28 2017-12-05 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US9968594B2 (en) 2013-08-28 2018-05-15 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US9089562B2 (en) * 2013-08-28 2015-07-28 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
RU2533276C1 (ru) * 2013-10-09 2014-11-20 Станислав Анатольевич Кедик Глазные капли на основе композиции фармацевтически приемлемой аддитивной соли кислоты и метилэтилпиридинола и таурина, содержащие композицию витаминов группы в
RU2528912C1 (ru) * 2013-10-09 2014-09-20 Станислав Анатольевич Кедик Глазные капли на основе композиции фармацевтически приемлемой аддитивной соли кислоты и метилэтилпиридинола, содержащие композицию витаминов группы в
EA034726B1 (ru) * 2014-02-25 2020-03-13 Общество С Ограниченной Ответственностью "Митотех" Косметическая композиция на основе митохондриально-адресованных антиоксидантов
DE102014007423A1 (de) * 2014-05-22 2015-11-26 Bitop Ag Zusammensetzung zur Behandlung des Auges
EP3148520A4 (en) * 2014-05-30 2018-01-10 Friedhoff, Lawrence, T. Antimicrobial pharmaceutical compositions with multiple drug resistance inhibiting properties
WO2016013993A1 (en) 2014-07-25 2016-01-28 Imuneks Farma Llac Sanayi Ve Ticaret A.Ş. Stable preservative free ophthalmic formulations of opioid antagonists
WO2016200364A1 (en) * 2015-06-08 2016-12-15 Stealth Peptides International, Inc. THERAPEUTIC COMPOSITIONS INCLUDING SkQ COMPOUNDS AND USES THEREOF
CN107312194A (zh) * 2017-07-13 2017-11-03 温州嘉泰乳胶制品有限公司 乳胶固化配方工艺
WO2019204401A1 (en) * 2018-04-19 2019-10-24 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US20210251970A1 (en) 2018-10-10 2021-08-19 Presbyopia Therapies Inc Compositions and methods for storage stable ophthalmic drugs
CN111351886B (zh) * 2018-12-24 2023-06-23 成都平和安康医药科技有限公司 一种测定酚磺乙胺药物中含有的杂质及其主药含量的方法
EP4072512A4 (en) * 2019-12-10 2024-01-10 Mitotech S.A. POLYMERIC MATRIXES FOR DIFFERENT COMPOSITIONS OF MITOCHONDRIAL TARGETED ANTIOXIDANTS
EP4125867A1 (en) * 2020-04-03 2023-02-08 Mitotech S.A. Use of mitochondria-targeted antioxidants to treat severe inflammatory conditions
RU2768752C1 (ru) * 2020-12-24 2022-03-24 Общество с ограниченной ответственностью "Международная лаборатория "Резистом" Противовирусная композиция для защиты растений на основе поли(а):поли(у)
EP4433053A4 (en) 2021-11-17 2025-09-17 Lenz Therapeutics Operations Inc ACECLIDINE DERIVATIVES, THEIR COMPOSITIONS AND METHODS OF USE
US11648247B1 (en) 2021-12-16 2023-05-16 Lenz Therapeutics, Inc. Compositions and methods for the treatment of presbyopia
CN116270630A (zh) * 2023-04-03 2023-06-23 爱尔眼科医院集团股份有限公司 巴马汀在制备治疗眼部疾病的药物中的用途
US12414942B1 (en) 2024-03-15 2025-09-16 Lenz Therapeutics Operations, Inc. Compositions, methods, and systems for treating presbyopia

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07252149A (ja) * 1994-01-27 1995-10-03 Senju Pharmaceut Co Ltd 眼科用剤
US5538974A (en) * 1994-01-27 1996-07-23 Senju Pharamceutical Co., Ltd. Ophthalmic composition for lowering intraocular pressure
US5535974A (en) * 1994-03-07 1996-07-16 Savitski; Richard H. Scaffold bracket
NZ505352A (en) 1997-11-25 2002-12-20 Univ Otago Mitochondrially targeted antioxidants
US6331532B1 (en) 1998-11-25 2001-12-18 University Of Otago Mitochondrially targeted antioxidants
US20080275005A1 (en) 1998-11-25 2008-11-06 Murphy Michael P Mitochondrially targeted antioxidants
US20070270381A1 (en) 2000-05-25 2007-11-22 Antipodean Pharmaceuticals, Inc. Mitochondrially targeted antioxidants
JP2001172183A (ja) * 1999-12-21 2001-06-26 Wakamoto Pharmaceut Co Ltd 眼科用医薬組成物
US20020044913A1 (en) 2000-02-11 2002-04-18 Hamilton Nathan D. Cosmetics to support skin metabolism
JP4859283B2 (ja) * 2001-05-23 2012-01-25 学校法人近畿大学 高安定性抗白内障医薬組成物
ITRM20010755A1 (it) 2001-12-20 2003-06-20 Simonelli Giuseppe Uso del chinone q10 per il trattamento delle malattie oculari.
CA2397684A1 (en) 2002-08-12 2004-02-12 Michael P. Murphy Mitochondrially targeted antioxidants
KR101003960B1 (ko) * 2003-08-22 2010-12-30 안티포딘 파마슈티칼스, 인코포레이티드 미토콘드리아 표적화 산화방지제로서 사용되는 미토퀴논 유도체를 포함하는 약제학적 조성물
US7514461B2 (en) 2003-09-19 2009-04-07 Edison Pharmaceuticals, Inc. Chroman derivatives
RU2007105138A (ru) 2004-07-13 2008-08-20 Оридис Биомед Форшунгс-Унд Энтвиклунгс Гмбх (At) Применение митохондриально направленного антиоксиданта при лечении болезней печени и эпителиальных раковых опухолей
US20070259908A1 (en) 2004-08-30 2007-11-08 Kaneka Corporation Mitochondria Activators
RU2318500C2 (ru) 2005-10-18 2008-03-10 Общество С Ограниченной Ответственностью "Митотехнология" Способ воздействия на организм путем адресной доставки биологически активных веществ в митохондрии, фармацевтическая композиция для его осуществления и соединение, применяемое для этой цели
US8658624B2 (en) * 2006-10-20 2014-02-25 Mitotech Sa Pharmaceutical compositions for preventing and treating eye pathologies
US8518915B2 (en) 2007-06-29 2013-08-27 Mitotech Sa Use of mitochondrially-addressed compounds for preventing and treating cardiovascular diseases
JP2009091175A (ja) * 2007-10-04 2009-04-30 Sumitomo Electric Ind Ltd ＧａＮエピタキシャル基板、半導体デバイス、ＧａＮエピタキシャル基板及び半導体デバイスの製造方法
EP2303824B1 (en) 2008-06-25 2015-03-25 Edison Pharmaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
EA201101576A1 (ru) * 2009-04-28 2012-04-30 Эдисон Фармасьютикалз, Инк. Лекарственная форма токотриенол хинонов для лечения офтальмических (глазных) заболеваний

Also Published As

Publication number Publication date
EA025414B1 (ru) 2016-12-30
CN107362157B (zh) 2022-08-26
EP2441453A4 (en) 2013-04-10
US10213392B2 (en) 2019-02-26
CA2764481A1 (en) 2010-12-16
US20120094962A1 (en) 2012-04-19
KR20130082069A (ko) 2013-07-18
KR101478728B1 (ko) 2015-01-02
JP5659388B2 (ja) 2015-01-28
AU2009347921B8 (en) 2014-07-24
US9724313B2 (en) 2017-08-08
CN102548548B (zh) 2017-09-01
EA201101518A1 (ru) 2012-04-30
AU2009347921B2 (en) 2014-07-17
ES2527791T3 (es) 2015-01-29
UA104320C2 (ru) 2014-01-27
US20170304225A1 (en) 2017-10-26
CN107362157A (zh) 2017-11-21
JP2012529504A (ja) 2012-11-22
BRPI0924460A2 (pt) 2018-03-27
EP2823814A1 (en) 2015-01-14
ZA201200111B (en) 2012-09-26
EP2441453A1 (en) 2012-04-18
EP2441453B1 (en) 2014-11-26
CN102548548A (zh) 2012-07-04
AU2009347921A1 (en) 2012-01-19
WO2010143990A1 (ru) 2010-12-16
CA2764481C (en) 2015-11-24
IL216702A0 (en) 2012-02-29

Similar Documents

Publication Publication Date Title
MX2011013150A (es) Composicion farmaceutica para uso en oftalmologia medica y veterinaria.
CY1119616T1 (el) Συζευγματα ανθρωπινου αντισωματος-φαρμακου κατα του ιστικου παραγοντα
DOP2011000343A (es) Derivados de piridina tieno [2,3-b] como inhibidores de replicacion viral
IN2012DN06720A (es)
MX2015003653A (es) Derivados de amida del acido benzoimidazol-carboxilico como moduladores del receptor apj.
JO3265B1 (ar) مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
WO2013186777A3 (en) Use of blocking agents of bone morphogenie protein (bmp) signaling for the treatment of neuroinflammatory and neurodegenerative diseases
SG10201805552PA (en) Sodium channel modulators for the treatment of pain and diabetes
WO2015128403A3 (en) An a22k, desb27, b29r, des b30, at epsilon position of lysine 22 acylated human insulin analogue
ZA202406617B (en) Insulin containing pharmaceutical compositions
GB0620385D0 (en) Novel compounds
UA104988C2 (uk) Похідні піроніндолу та спосіб їх отримання
MX2018002223A (es) Derivados de insulina novedosos y usos medicos de los mismos.
WO2011058245A8 (fr) Nouveaux derives de mannopyranoside ayant une activite anticancereuse
IN2015DN03921A (es)
CO6180495A2 (es) Formulacion de medicamento liquida
MX364652B (es) Formulacion farmaceutica que comprende ciclesonida.
IL217519A (en) Tazarotene derivatives, pharmaceutical compositions comprising them and use thereof for the manufacture of medicaments for the treatment of skin disorders
CY1111361T1 (el) Νεα προσδεματα συναγωνιστες των υποδοχεων rar, χρηση στην ανθρωπινη ιατρικη καθως και στην κοσμετολογια
PH12015500070B1 (en) Pediatric oral liquid compositions containing nepadutant
NZ703729A (en) Combinations with a backbone-cyclized peptide
CR20220620A (es) Composición farmacéutica acuosa de levilimab y su uso
SG11201806628UA (en) New bi-aromatic propynyl compounds, pharmaceutical and cosmetic compositions containing them and uses thereof
MY159675A (en) Clerodane derivatives for modulation of leukotriene receptor activity and related diseases
EA201992775A2 (ru) Конъюгаты антител человека против тканевого фактора с лекарственными препаратами

Legal Events

Date Code Title Description
FG Grant or registration